Johnson & Johnson has expanded its consumer health product offering in the UK by securing the Rx-to-OTC switch of its Sudafed Plus Blocked Nose nasal spray.
UK Product Approvals: J&J Expands Sudafed And Nicorette Offerings
The UK's MHRA has approved the Rx-to-OTC switch of J&J's Sudafed Plus nasal spray (xylometazoline hydrochloride/dexpanthenol) and given the green light for the company to add new pack sizes to its Nicorette QuickMist and QuickMist Smart Track products.
More from Rx-to-OTC Switch
• By
Eisai aims to support people in Japan with severe heartburn and discomfort caused by gastric acid related conditions by switching from prescription to OTC status its Pariet-branded proton pump inhibitor.
• By
Two AESGP papers reviewing the evidence for AMR risk associated with a range of OTC antifungals and antivirals conclude there is litte to no risk associated with the responsible self-care use of such medicines.
• By
HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.
• By
“Overall, no unexpected/new data or findings” were presented to Germany's Expert Committee for Prescription in the most recent Rx-to-OTC switch application for sildenafil (25mg and 50mg), according to medicines regulator BfArM, resulting in a third rejection in three years.
More from Health
• By
Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.
• By
Jump in cough & cold sales at the end of the year helps Recordati post higher OTC revenues for 2024.
• By
Italy's Alfasigma has expanded its operation in Germany with the creation of a new Consumer Healthcare unit. Led by Rüdiger Hoppe, the business is rolling out OTC medical devices and dietary supplements in the gastrointestinal category.